Engineered immune cells take on deadliest brain cancer
NCT ID NCT06482905
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new treatment called TX103 CAR-T cells for people with recurrent or progressive grade 4 glioma, a very aggressive brain cancer. The treatment involves taking a patient's own immune cells, engineering them to recognize and attack cancer cells, and infusing them back. The main goals are to check safety and find the best dose, with 52 participants enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TX103 CAR-T cells (immune cells engineered to target B7-H3 on cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for people with recurrent grade 4 glioma, a very aggressive brain cancer.
What could go wrong
This is a very early (Phase 1) and small trial (52 people) focused on safety and dosing. CAR-T therapy can cause serious side effects like cytokine release syndrome, and it's unknown if it will shrink tumors or extend survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tiantan Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mayo Clinic in Arizona
RECRUITINGPhoenix, Arizona, 85054, United States
Contact
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224, United States
Contact
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Email: •••••@•••••